ARS Pharmaceuticals Inc (NASDAQ: SPRY) kicked off on Tuesday, up 5.76% from the previous trading day, before settling in for the closing price of $13.20. Over the past 52 weeks, SPRY has traded in a range of $2.55-$16.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -34.76% over the past five years. While this was happening, its average annual earnings per share was recorded -12.72%. With a float of $47.68 million, this company’s outstanding shares have now reached $96.41 million.
Let’s look at the performance matrix of the company that is accounted for 26 employees. In terms of profitability, gross margin is 86.81%, operating margin of -12071.49%, and the pretax margin is -9536.81%.
ARS Pharmaceuticals Inc (SPRY) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of ARS Pharmaceuticals Inc is 50.82%, while institutional ownership is 37.73%. The most recent insider transaction that took place on Aug 21 ’24, was worth 5,526,601. In this transaction Director of this company sold 407,700 shares at a rate of $13.56, taking the stock ownership to the 544,677 shares. Before that another transaction happened on Aug 22 ’24, when Company’s Director sold 391,482 for $12.94, making the entire transaction worth $5,065,777. This insider now owns 153,195 shares in total.
ARS Pharmaceuticals Inc (SPRY) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.16 earnings per share (EPS), higher than consensus estimate (set at -0.18) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.72% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Take a look at ARS Pharmaceuticals Inc’s (SPRY) current performance indicators. Last quarter, stock had a quick ratio of 32.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2706.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc (NASDAQ: SPRY) saw its 5-day average volume 1.38 million, a positive change from its year-to-date volume of 0.72 million. As of the previous 9 days, the stock’s Stochastic %D was 30.32%. Additionally, its Average True Range was 0.97.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 71.62%, which indicates a significant increase from 63.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.98% in the past 14 days, which was higher than the 64.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.63, while its 200-day Moving Average is $8.22. Nevertheless, the first resistance level for the watch stands at $14.27 in the near term. At $14.58, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.11. If the price goes on to break the first support level at $13.43, it is likely to go to the next support level at $12.90. The third support level lies at $12.59 if the price breaches the second support level.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
The company with the Market Capitalisation of 1.35 billion has total of 96,895K Shares Outstanding. Its annual sales at the moment are 30 K in contrast with the sum of -54,370 K annual income. Company’s last quarter sales were recorded 500 K and last quarter income was -12,520 K.
